Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jules Heuberger

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|May 8, 2013
When is protein binding important?Jules Heuberger, Stephan Schmidt, Hartmut Derendorf
Medicinal Research Reviews|May 29, 2015
Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled ReceptorsMaris Vilums, Jules Heuberger, Laura H Heitman, et al.
Psychiatry Research|December 3, 2014
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinolDaniël Kleinloog, Jasper Stevens, Jules Heuberger, et al.
The AAPS Journal|August 31, 2013
A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantationSherwin K B Sy, Jules Heuberger, Sireen Shilbayeh, et al.
Clinical Pharmacology and Therapeutics|February 16, 2018
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human StudyClemens Muehlan, Jules Heuberger, Pierre-Eric Juif, et al.
British Journal of Clinical Pharmacology|December 1, 2015
Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge testsZheng Guan, Linda E Klumpers, Olubukayo-Opeyemi Oyetayo, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve IndividualsMarijke Hyke Algera, Erik Olofsen, Laurence Moss, et al.
Clinical Therapeutics|February 13, 2017
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple SclerosisGuido van Amerongen, Kawita Kanhai, Anne Catrien Baakman, et al.
Neuromuscular Disorders : NMD|December 17, 2018
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophyHeidemarie Kletzl, Anne Marquet, Andreas Günther, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|May 8, 2013
When is protein binding important?Jules Heuberger, Stephan Schmidt, Hartmut Derendorf
Medicinal Research Reviews|May 29, 2015
Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled ReceptorsMaris Vilums, Jules Heuberger, Laura H Heitman, et al.
Psychiatry Research|December 3, 2014
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinolDaniël Kleinloog, Jasper Stevens, Jules Heuberger, et al.
The AAPS Journal|August 31, 2013
A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantationSherwin K B Sy, Jules Heuberger, Sireen Shilbayeh, et al.
Clinical Pharmacology and Therapeutics|February 16, 2018
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human StudyClemens Muehlan, Jules Heuberger, Pierre-Eric Juif, et al.
British Journal of Clinical Pharmacology|December 1, 2015
Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge testsZheng Guan, Linda E Klumpers, Olubukayo-Opeyemi Oyetayo, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve IndividualsMarijke Hyke Algera, Erik Olofsen, Laurence Moss, et al.
Clinical Therapeutics|February 13, 2017
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple SclerosisGuido van Amerongen, Kawita Kanhai, Anne Catrien Baakman, et al.
Neuromuscular Disorders : NMD|December 17, 2018
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophyHeidemarie Kletzl, Anne Marquet, Andreas Günther, et al.
Pageof 1